Review Article
Roles of Steroids in Preventing Esophageal Stricture after Endoscopic Resection
Table 2
Clinical outcomes of local steroid injection of preventing esophageal stricture after endoscopic resection.
| Author, year | Design | Setting | Sample size (treated/control) | Follow-up | Stricture rate | Mean or median number of EBD | Adverse event |
| Tsujii, 2017 [50] | Retrospective study | ESD>75% SENs | 28/10 | Gastroscopy: a few months after ESD | 43% VS 90% (P=0.012) | 8 VS 5 (P>0.05) | 5 VS 1 | Yasuaki, 2017 [52] | Retrospective study | ESD>2/3but <100% SENs | 37/37 | Gastroscopy: every 4 weeks after ESD or receiving complaints of dysphagia | 18.9% VS 45.9% (P=0. 016) | 0.6±1.5 VS 2.8±4.6 (P<0.01) | None | Furuhashi, 2017 [53] | Historical control study | ESD≥30mm diameter or ≥3/4 | 43/25 | Not mentioned | Multivariate analysis: OR:0.041,95%CI:0.007 to 0.24, p<0.001 | 2.3 VS 10.9 | None | Xu, 2016 [46] | Randomized controlled trial | ESD≥1/2 SENs | 17/23 | Not mentioned | 29.4% VS 69.6% (P=0.02) | 0.5 VS 1.3 (P=0.16) | 1 VS 0 | Yoshiki, 2016 [49] | Retrospective study | ESD>1/2 SENs | 30/15 | Not mentioned | 40% VS 60% (P>0.05) | Not significantly different | 6 VS 0 | Yasuaki, 2016 [47] | Retrospective study | >2/3but<3/4 ESCC | 28/28 | Gastroscopy: 4 and 8 weeks after the treatment. | 10.7% VS 35.7% (P=0.035) | Not mentioned | Not mentioned | Takahashi, 2015 [45] | Prospective study | ESD>75% ESCC | 16/16 | Not mentioned | 62.5% VS 87.5% (P=0. 22) | 6.1 VS 12.5 (P=0.04) | 1.0% VS 0. 5% | Lee, 2013 [66] | Case report | ESD 100% ESCC | 1/0 | Gastroscopy: 2 and 4 weeks and 4 months after ESD. Total follow-up time lasts for 6 months. | 0% | 0 | None | Hanaoka, 2012 [44] | Prospective study | ESD>75% but<100% ESCC | 30/29 | Gastroscopy: whenever patients reported dysphagia and 2 months after ESD in patients without dysphagia. | 10% VS 66% (P<0.0001) | 0 VS 2 (P<0.0001) | 2 VS 0 | Satoru,2011 [7] | Retrospective | ESD >75% ESCC | 21/20 | Gastroscopy: assess for stenosis at 1 week, 1 month, 6 months, and 1 year after ETI. | 19% VS 75% (P<0.001) | 1.7 VS 6.6 (P<0.001) | None |
|
|
SENs, superficial esophageal neoplasms; LSI, local steroid injection; DSP, dexamethasone sodium phosphate; TA, triamcinolone acetonide; TTI, topical triamcinolone injection; ESCC, esophageal squamous cell carcinoma.
|